For Older Men, Digital Rectal Exams Continue to Be Important Prostate Screening Tools

Published Online: Thursday, April 18, 2013
Follow Pharmacy_Times:
Despite the fact that an elevated level of prostate-specific antigen (PSA) in the blood has been shown to better predict a positive cancer biopsy result than a digital rectal exam (DRE), the rectal exam is still a necessary screening method for older men with higher, age-adjusted PSA levels, according to a study published in the December 2012 issue of The Canadian Journal of Urology.

Penn State College of Medicine researchers sought to determine the effectiveness of the digital rectal exam in predicting prostate cancer when compared with a PSA test in older men. Because PSA levels naturally increase in men as they age, the researchers were interested in determining how age-specific cutoff rates could contribute to limitations in using the PSA test as the only cancer-screening method.

The researchers studied 806 men undergoing prostate needle biopsy from September 2001 to December 2008. They compared the results of initial testing with biopsy results for each of the participants. Of the 306 men determined to have prostate cancer, 136 had an abnormal DRE. Of the 136 with abnormal DRE results, 43 patients (or 31%) had normal PSA levels for their age.

“Our study confirms that the digital rectal exam remains an important part of screening [such] patients because 31% of cancers in our study would have been missed by using age-specific PSA cutoffs alone,” concluded the study authors.

Related Articles
Abiraterone acetate (Zytiga) significantly prolongs survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
Teikoku Pharma USA has submitted a New Drug Application to the FDA for the product.
Although testosterone is often considered to be a catalyst of prostate cancer, a recent study suggests that the hormone may be able to subdue advanced prostate cancer and break down resistance to testosterone-blocking drugs used to treat the disease.
A vaccine therapy that stimulates the body’s own immune defenses is safe to give to prostate cancer patients early in the disease’s progression, a recent study found.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$